Mental Health Medication Management: Why Continuity Is the Missing Piece

Psychiatric medication works. The system built around it, most of the time, does not.

Your brain chemistry does not know what month it is. Serotonin and norepinephrine signaling do not care about your prescriber's calendar. The neurochemical adjustments that antidepressants require, the receptor sensitization shifts, the downstream signaling changes, the clinical window for assessing whether a dose is working, these happen in your nervous system every day, including the 89 days between quarterly appointments.

The standard care model for psychiatric medication management was built around a constraint, not a clinical ideal. Psychiatrist shortages are real. There is roughly one psychiatrist for every 1,200 Americans who need mental health treatment, according to SAMHSA data. Quarterly appointments are what the workforce can sustain, not what the research says produces the best outcomes. When you see your prescriber for 15 minutes every three months, the interval between visits is not a clinical design choice. It is a system limitation that most patients are quietly absorbing the consequences of.

The gap between appointments is where medication management happens, or fails to happen. It is where nausea in week two becomes a reason to stop. It is where "I feel better" becomes a reason to taper. It is where a dose that should have been adjusted six weeks ago stays the same because there was no mechanism to catch the signal. And it is where, for nearly half of all psychiatric patients, the treatment plan gradually comes apart without anyone noticing until the next appointment.

What Continuity of Care Actually Means in Psychiatric Medication

Continuity of care is often described as seeing the same doctor. That is one component of it, but it is not the whole picture. A prospective cohort study published in BMC Psychiatry found that higher continuity of care in psychiatric patients significantly reduced symptom severity and improved social functioning, with medium effect sizes that were time-independent. The mechanism is not just familiarity. It is that the clinical history accumulates across appointments, and decisions are made with the benefit of a longitudinal record rather than a reconstruction.

In psychiatric medication management, continuity has three distinct dimensions that patients and prescribers often conflate. Informational continuity means that the prescriber has access to your complete treatment history, including what you have tried, what worked partially, what caused side effects, and what your symptom baseline looked like before and during treatment. Management continuity means that the clinical plan is adjusted based on actual data about how you are doing, not just your verbal report at a follow-up. Relational continuity means you see the same clinician who holds your history over time.

Most patients get fragments of these. A prescriber who sees you once a quarter for 15 minutes has relational continuity in name only. If the follow-up visit consists of "how are you feeling?" with no structured symptom data, the informational and management dimensions are missing even when the same person shows up.

What Happens in the Gap Between Appointments

A systematic review and meta-analysis of 35 studies found that approximately 49% of patients with major psychiatric disorders do not adhere to their prescribed psychotropic medication regimen. The rate for major depressive disorder specifically was 50%. For many of these patients, the decision to stop or reduce their medication happened between appointments, when no one was monitoring and no one was available to address the reason.

The pattern is predictable. Research from the Mental Health Research Network found that approximately 30% of patients discontinue antidepressants within the first month, and up to 60% have stopped by three months. The critical window is the early weeks of treatment, when side effects are most prominent and the clinical benefit has not yet reached full expression. A patient who starts sertraline and develops nausea, headaches, or sleep disruption in weeks one and two is experiencing common and typically transient side effects. But if no one is checking in and no one has explained what to expect, stopping is a rational response.

This is not a patient failure. It is a monitoring failure. The side effects that drive early discontinuation are well-documented and, in most cases, addressable with dose timing adjustments, titration, or simple education about the expected trajectory. What converts a manageable early side effect into discontinuation is the absence of someone checking whether the patient is experiencing it.

The Three Forms of Continuity Most Patients Never Get

Provider Continuity

Seeing the same prescriber who holds your full clinical history produces meaningfully different care than cycling through whoever is available at the next appointment. The prescriber who reviewed your intake, approved your initial plan, and has access to structured data on your check-ins is making a different quality of clinical judgment than one meeting you for the first time at a follow-up. Research has associated prescriber continuity with better medication adherence, lower emergency department visits, and reduced hospitalization rates in patients with psychiatric conditions.

Information Continuity

This is the clinical record problem. Information continuity means the prescriber seeing you today has access to everything that happened between the last visit and this one: not your verbal summary, which is shaped by recency bias and what you remember to mention, but structured data on your symptoms, sleep, mood, and side effects over the weeks since your last appointment. Without this, your prescriber is making decisions based on a snapshot rather than a trajectory. A dose that has been producing side effects for six weeks but that you have been tolerating silently is invisible at a 15-minute appointment unless someone was tracking it.

Management Continuity

Management continuity is the most clinically significant and the least commonly achieved. It means your treatment plan is being actively adjusted based on observed response, not maintained unchanged until you flag a problem. Dose optimization happens because the data shows it is warranted. Side effect management happens because the data shows a side effect is present. The escalation decision happens because the monitoring structure caught a worsening trend. Without management continuity, psychiatric care is reactive: waiting for the patient to report a problem at the next visit rather than catching it in the data between visits.

Why the Standard Appointment Schedule Was Never Designed to Track Medication Response

The quarterly follow-up model was not designed around the clinical timeline of psychiatric medication. SSRIs and SNRIs require four to eight weeks to reach full therapeutic effect, and the period of greatest clinical risk, where side effects are highest and the probability of early discontinuation is greatest, falls entirely within that window. A prescriber who sees a patient at week twelve, after the acute phase has passed and the patient has either stayed on the medication or stopped it, is not positioned to intervene when intervention is most needed.

The American Psychiatric Association's practice guidelines for major depressive disorder recommend follow-up within the first two to four weeks of a new antidepressant trial. In practice, workforce constraints mean that recommendation is routinely unmet. The patient who starts a new medication and encounters nausea by day five has no clinical contact until their next scheduled appointment, which may be six weeks away.

A 2021 study published in the New England Journal of Medicine followed patients who felt well enough to stop their antidepressants. Among those who stopped, 56% experienced a relapse within 52 weeks, compared to 39% of those who maintained their therapy, with a hazard ratio of 2.06. The patients who stopped were not making an irrational decision. They felt better. The issue is that "feeling better" on antidepressants does not reliably signal that the underlying vulnerability has resolved. Maintaining the gains requires maintaining the treatment, and that requires a system that communicates this and monitors what happens when the decision is being considered.

What Between-Visit Monitoring Changes

Research published in JMIR Formative Research found that among patients with severe baseline scores for anxiety and depression, more frequent digital engagement was associated with meaningfully better clinical outcomes over a six-month period. Participants who engaged every other day showed greater reductions in both anxiety and depression scores than those who engaged less frequently. The monitoring structure is not incidental. It is the mechanism by which continuity produces clinical benefit.

What between-visit monitoring changes is the information available to make decisions. A prescriber working from a structured daily symptom log knows whether week three of a new antidepressant brought the expected transient increase in anxiety before stabilization, or whether week five still shows no improvement and the dose should be adjusted. They know whether the side effect mentioned at the last visit resolved or has been quietly present for six more weeks. They know whether the pattern they are seeing now resembles the pattern from three months ago, before the last dose change.

This is not surveillance. It is clinical data. And the absence of it is why most medication management decisions in outpatient psychiatry are made with less information than they should be.

How SiggyMD Builds Continuity In

SiggyMD was built around the parts of the care model that consistently break down. The anonymous intake captures a complete clinical picture before any prescriber sees you, so the first clinical review starts with actual history rather than a reconstructed summary. That history goes to a licensed prescriber who reviews the full clinical picture, the PHQ-9, the treatment goals, and the specific clinical considerations the intake identified, before approving a treatment plan. Nothing moves forward without that review.

After the plan is approved, the daily check-in structure provides the between-visit monitoring that most patients never receive. Your prescriber is not waiting for your next quarterly visit to know whether the medication is working. They have structured data on your symptom trajectory, sleep, mood, and side effects across the days since treatment began.

"Continuity in psychiatric care is often described as if it just means seeing the same doctor," says Daniel Montville, MD, of the SiggyMD clinical team. "What it actually means is that someone is watching how your treatment is going, between visits, in real time. Without that, you are not managing a treatment plan. You are writing prescriptions and hoping."

The care team has access to the full longitudinal record: not just what you reported at the last appointment, but the trajectory over time. That is what makes the difference between a dose adjustment happening when the data shows it is warranted and a dose adjustment happening six months later when the patient finally mentions it.

What Members Are Saying

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Frequently Asked Questions

What Is Continuity of Care in Mental Health Medication Management?

Continuity of care in psychiatric medication management involves three distinct dimensions: provider continuity (seeing the same clinician over time), informational continuity (that clinician having access to your complete treatment history, not just your verbal report), and management continuity (active adjustment of the treatment plan based on observed data). Most patients experience fragments of these. Genuine continuity requires all three working together across the full span of treatment.

Why Do So Many People Stop Their Antidepressants?

Approximately 30% of patients stop their antidepressant within the first month, and up to 60% stop within three months. The primary drivers are side effects in the early weeks before clinical benefit develops, the absence of anyone checking in to manage those side effects, and the common misread that feeling better means it is safe to stop. These are structural failures, not patient failures. The medication would likely have worked if the monitoring structure had been in place to support staying on it through the difficult phases.

What Happens If I Stop My Antidepressant When I Feel Better?

A 2021 randomized controlled trial published in the New England Journal of Medicine found that patients who stopped their antidepressants when they felt well enough had a 56% relapse rate within 52 weeks, compared to 39% for those who maintained therapy, with a hazard ratio of 2.06. Stopping when you feel better is understandable, but it carries meaningfully elevated relapse risk. The decision should be made with a prescriber who can review your symptom trajectory and discuss supervised tapering vs. abrupt discontinuation.

How Often Should I Have Follow-Up With My Prescriber on Antidepressants?

The American Psychiatric Association's practice guidelines recommend follow-up within the first two to four weeks of a new antidepressant trial. The highest-risk period is the acute phase, when side effects are most prominent and clinical benefit has not fully developed. Between-visit monitoring through structured check-ins can extend this clinical coverage between scheduled appointments and provides the prescriber with real-time data rather than reconstructed summaries.

What Is the Difference Between Medication Continuity and a Prescription Refill?

A prescription refill continues a medication without clinical evaluation. Medication continuity means the continuation decision is being made by someone who has reviewed how you have been doing since the last visit, whether the medication is producing the intended therapeutic effect, whether side effects have emerged, and whether the current dose is still appropriate. The first is a transaction. The second is clinical care. The distinction matters most during the first several months of a new antidepressant trial.

What Does Measurement-Based Care Mean in Psychiatry?

Measurement-based care refers to using validated clinical instruments, such as the PHQ-9 for depression or the GAD-7 for anxiety, at regular intervals to assess treatment response and guide clinical decisions. The standard of care in psychiatry recommends it, but it requires data collection at regular intervals, not just at scheduled appointments. Between-visit monitoring is central to implementing measurement-based care in practice, not just in principle.

Bottom Line

Mental health medication management does not fail because medications do not work. It fails, most of the time, because the structure around the medication does not provide what patients need to stay on it, manage it, and benefit from it over time.

Continuity is not a nice-to-have. It is the clinical mechanism by which psychiatric medication produces lasting benefit. Provider continuity, information continuity, and management continuity together create the conditions where a prescriber can catch early signals, make timely adjustments, and intervene before the pattern that usually ends in discontinuation takes hold.

If your current psychiatric care consists of a quarterly prescription refill with no between-visit monitoring and no structured mechanism to track whether the medication is working, what you have is not medication management. It is medication maintenance. The distinction matters, especially if you have been on the same plan for months and are not entirely sure it is still serving you.

Sources

1. Semahegn A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Systematic Reviews. 2020;9(1):17.
2. Rossom RC, et al. Antidepressant adherence across diverse populations and healthcare settings. Depression and Anxiety. 2016;33(8):765-774.
3. Lewis G, et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine. 2021;385:1257-1267.
4. de Cruppé W, et al. Association between continuity of care and treatment outcomes in psychiatric patients in Germany: a prospective cohort study. BMC Psychiatry. 2023;23(1).
5. Dzubur E, et al. The Effect of a Digital Mental Health Program on Anxiety and Depression Symptoms: Retrospective Analysis of Clinical Severity. JMIR Formative Research. 2023;7:e36596.
6. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA. Accessed May 2026.
7. Substance Abuse and Mental Health Services Administration. 2024 National Survey on Drug Use and Health. SAMHSA. July 2025.
8. American Psychiatric Association. What Is Telepsychiatry? APA Patient Resources. Accessed May 2026.